Aligos Completes Phase 2 B-SUPREME Enrollment
SOUTH SAN FRANCISCO, Calif., July 13, 2026 Aligos Therapeutics announced the completion of patient enrollment in both parts of...
Liver Disease
Advertisement
Aligos Secures $25M Upfront in Greater China Deal
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop...
GENFIT Secures U.S. Medicare Coverage for NASHnext Diagnostic Test
Lille, France; Cambridge, Massachusetts, United States; and Zurich, Switzerland, July 2, 2026 GENFIT announced that U.S. Medicare has approved...
AbbVie Secures EU Approval for MAVIRET in Acute Hepatitis C
NORTH CHICAGO, Ill., June 23, 2026 AbbVie announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir) for the treatment...
insitro Advances AI-Discovered CTRO-1013 for MASH With Anti-Fibrotic Data
NEW ORLEANS, June 8, 2026 insitro announced new preclinical findings from its lead metabolic dysfunction-associated steatohepatitis (MASH) program, demonstrating...
Advertisements
Gilead’s Livdelzi Achieves Key Phase 3 PBC Trial Goal
FOSTER CITY, California, USA, June 2, 2026 Gilead Sciences has announced positive topline results from the Phase 3 IDEAL...
FDA Grants Priority Review to Zydus Therapeutics’ Saroglitazar for Rare Liver Disease
PENNINGTON, New Jersey and AHMEDABAD, India, May 28, 2026 Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, has...
Brii Bio Reports Positive ENSURE HBV Cure Study Results
DURHAM, N.C. and BEIJING, China, May 27, 2026 Brii Biosciences Limited (Brii Bio) has presented new late-breaking clinical and...
Gilead Reports Strong Long-Term Livdelzi PBC Data
FOSTER CITY, Calif., May 28, 2026 Gilead Sciences announced new interim findings from the ongoing Phase 3 ASSURE study...
Precision BioSciences Reveals Breakthrough HBV Data
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
Advertisement
